Capecitabine, alone and in combination, in the management of patients with colorectal cancer: A review of the evidence

Drugs

Volumn 68, Issue 7, 2008, Pages 949-961

  Comella, Pasquale ^a   Casaretti, Rossana ^a   Sandomenico, Claudia ^a   Avallone, Antonio ^a   Franco, Luca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Capecitabine, therapeutic use; Colorectal cancer, treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTERY THROMBOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; METASTASIS; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS;

EID: 43249090877     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868070-00005     Document Type: Review

References (70)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 575-4580
3. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-75
4. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300
5. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355: 1588-96
6. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 15: 1797-806
7. André T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-903
8. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 38: 1274-81
9. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer. Biochem Pharmacol 1998; 55: 1091-7
10. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-45
11. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92
12. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106
13. Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Capecitabine Colorectal Cancer Group. Eur J Cancer 2002; 38 Suppl. 2: 15-20
14. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997; 15: 808-15
15. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5
16. Twelves C, Gollins S, Grieve R, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 7: 239-45
17. Pfeiffer P, Mortensen JP, Bjerregaard B, et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006; 42: 2738-43
18. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol 2005; 23: 3104-11
19. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-14
20. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000; 355: 1041-7
21. Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 15: 279-87
22. Borner MM, Bernhard J, Dietrich D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005; 16: 282-8
23. Fuchs C, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007; 25: 4779-86
24. Köhne C, de Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2007; doi1093/annonc/mdm544: 10
25. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47
26. Pluzanska A, Mainwaring P, Cassidy J, et al. Final results of a randomized phase III study evaluating the addition of oxaliplatin first-line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study) [abstract no. 3517]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 250s
27. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) [abstract no. 512]. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18-21; Orlando (FL). Proc Am Soc Clin Oncol 2002; 21: 129a
28. Cassidy J, Tabernero J, Twelves CJ, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-209
29. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal cancer: final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0108. Cancer 2005; 104: 282-9
30. Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94: 969-75
31. Shields AF, Zalupski MM, Marshall JL, et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004; 100: 531-7
32. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-12
33. Comella P, Massidda B, Palmeri S, et al. Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. Cancer Chemother Pharmacol 2005; 56: 481-6
34. Martoni AA, Pinto C, Di Fabio F, et al. Capecitabine plus oxaliplatin (XELOX) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pviFOX) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer 2006; 42: 3161-8
35. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study [abstract no. 3510]. Presented at the 42nd Annual Meeting of the Americal Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). J Clin Oncol 2006; 24: 18S
36. Porschen R, Arkenau H-T, Kubicka S, et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer. A final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-23
37. Díaz-Rubio E, Tabernero J, Gómez-Espaňa J, et al. Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25: 4224-30
38. Ducreux M, Bennouna J, Hebbar M, et al. Efficacy and safety findings from a randomised phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) [abstract no. 4029]. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL). J Clin Oncol 2007; 25 (Pt I): 18S
39. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC) [abstract no. 270]. Presented at the GI Cancer Symposium 2007; 2007 Jan 19-21; Orlando (FL). J Clin Oncol 2007; 25: 4165
40. Comella P, Massidda B, Filippelli G, et al. Randomized comparison of capecitabine versus fluorouracil/leucovorin in combination with oxaliplatin in metastatic colorectal cancer patients: Southern Italy Cooperative Oncology Group trial 0401 [abstract no. 344]. Presented at the GI Cancer Symposium 2008; 2008 Jan 25-27; Orlando (FL)
41. Haller DG, Cassidy J, Clarke S, et al. Tolerability of fluoropyrimidines appears to differ by region [abstract no. 3514]. Presented at the 42nd Annual Meeting of the Americal Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). Proc Am Soc Clin Oncol 2006; 24: 18S
42. Rothenberg ML, Saltz L, Cunningham D, et al. Analysis of tolerability of fluoropyrimidines in combination with oxaliplatin by region [abstract no. 456]. Presented at the GI Cancer Symposium 2008; 2008 Jan 25-27; Orlando (FL)
43. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line metastatic colorectal cancer (MCRC) [abstract no. 238]. Presented at the GI Cancer Symposium 2007; 2007 Jan 19-21; Orlando (FL). J Clin Oncol. 2007; 25: 1539
44. Ramanathan RK, Clark JW, Kemeny NE, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003; 2: 2904-11
45. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-69
46. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-66
47. Pfeiffer P, Sørbye H, Ehrsson H, et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol 2006; 17: 252-8
48. Rothenberg ML, Navarro M, Butts C, et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC) [abstract no. 4031]. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL). J Clin Oncol 2007; 25 (Pt I): 18S
49. Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 24: 1892-7
50. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44
51. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-7
52. Sargent DJ, Goldberg RM, Jacobson SD, et al. A Pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-7
53. Twelves C, Wong A, Novacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-704
54. Twelves C, Scheithauer W, McKendrick J, et al. 5-Year overall survival update from the X-ACT trial of capecitabine vs 5-FU/LV as adjuvant treatment for stage III colon cancer [abstract no. 1LB]. Proceedings from the 14th European Cancer Conference. Eur J Cancer 2007; 5: 1
55. Schmoll HJ, Cartwright T, Tabernero JM, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer. J Clin Oncol 2007; 25: 102-7
56. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51
57. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years [abstract no. 4007]. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL). J Clin Oncol 2007; 25 (Pt I): 18S
58. Delcò F, Egger R, Bauerfeind P, et al. Hospital health care resource utilization and costs of colorectal cancer. Aliment Pharm Therap 2005; 21: 615-22
59. Van Custem E, Verslype C, Demedts I. The treatment of advanced colorectal cancer: where are we now and where do we go? Best Pract Res Clin Gastroenterol 2002; 16: 319-30
60. Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 52-8
61. Neymark N, Adriaenssen I. The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer 1999; 35: 1789-95
62. Redaelli A, Cranor CW, Okano GJ, et al. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003; 21: 1213-38
63. Uyl-de Grect CA, Giaccone G. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 2005; 17: 392-6
64. National Institute for Clinical Excellence (NICE) UK. Final appraisal determination: capecitabine and tegafur with uracil for metastatic colorectal cancer. London: NICE, 2003
65. Ward S, Kaltenthaler E, Cowan J, et al. The clinical and economic benefit of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006; 95: 27-34
66. James R, Bianco C, Farina C. Savings in staff time as a result of switching from De Gramont to oral capecitabine for patients with advanced colorectal cancer [abstract no. 271]. Proceedings from the 12th European Cancer Conference. Eur J Cancer 2003; 5: S83
67. Twelves C, Boyer M, Findlay M, et al, on behalf of the Colorectal Cancer Study Group. Capecitabine (Xeloda) improves medical resource use compared with 5-fluoruracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604
68. Giuliani G, Lucioni C, Mazzi S, et al. Economic evaluation of five chemotherapy regimens used in a Northern Italy hospital: oral capecitabine vs intravenous 5-FU/FA (Mayo regimen) in the treatment of advanced colorectal cancer. Pharmacoeconomics Italian Research Articles 2002; 4: 31-8
69. Jansman FGA, Postma MJ, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluoruracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004; 26: 579-89
70. Chu E, Diaz-Rubio E, Marshall J, et al. Economic analysis of potential medical cost savings of XELOX (capecitabine and oxaliplatin combination) in metastatic colorectal cancer [abstract no. 1080]. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 269